A full year of Zepbound\u00ae. That’\\”s 52 weekly injections, three or four dose adjustments, dozens of small course corrections, and a slowly shifting baseline. By the 12-month mark, most patients have done the heavy lifting of weight loss, and the curve is bending into the maintenance phase.<\/p>\n
The big number from SURMOUNT-1 (Jastreboff et al. 2022 NEJM): average weight loss at week 52 was 19.5 percent on the 10 mg arm and 21.4 percent on 15 mg. For a 240-pound adult, that’\\”s 47 to 51 pounds gone.<\/p>\n
The honest spread is wide. Patients in the top quartile reached 25 to 30 percent loss. Patients in the bottom quartile sat around 10 to 14 percent. Both groups are biologically normal responders.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The SURMOUNT-1 averages are 15.0 percent on 5 mg, 19.5 percent on 10 mg, and 21.4 percent on 15 mg at week 72.<\/strong> At the 52-week mark specifically, the numbers track slightly below those (about 17 to 20 percent on therapeutic doses) since weight loss continued through weeks 52 to 72 in many patients.<\/p>\n Quick Answer: SURMOUNT-1 reported 19.5 to 21.4 percent average weight loss at 1 year on therapeutic doses<\/p>\n For real-world expectation setting:<\/p>\n Patients combining the drug with serious strength training and protein-prioritized eating tend to land at the upper end of these ranges.<\/p>\n Because it’\\”s where the metabolic adaptation locks in.<\/strong> Year 1 is when the brain’\\”s set point starts shifting toward the new lower weight, which is the difference between sustainable weight loss and short-term diet results.<\/p>\n Studies of the National Weight Control Registry and follow-ups to STEP and SURMOUNT trials suggest that patients who maintain weight loss for 12 to 18 months have a meaningfully higher probability of long-term maintenance. The brain begins to defend the lower weight rather than the higher one, though this isn’\\”t absolute.<\/p>\n This is also the window where lifestyle habits become automatic. Protein-first meals, regular strength training, and adequate sleep should be running on autopilot by month 12.<\/p>\n Most are on 10 or 15 mg maintenance.<\/strong> The Eli Lilly labeling and SURMOUNT-1 protocol both centered on these as the long-term doses. About 65 to 75 percent of trial completers ended at one of these levels.<\/p>\n Some patients respond strongly to 5 mg and stay there indefinitely. Others rotate between 10 and 15 mg based on plateau patterns. There’\\”s no fixed answer.<\/p>\n What matters is the rate of weight loss vs side effect tolerance. If a patient is losing 0.5 to 1 pound per week comfortably on 10 mg, there’\\”s no reason to escalate. If weight loss has stalled for 6+ weeks and the patient is well below goal, advancing to 15 mg is reasonable.<\/p>\n A typical Zepbound year looks like this:<\/p>\n By month 12, most patients are losing 0.25 to 1 pound per week. Some have fully plateaued. Others continue to lose slowly through month 18.<\/p>\n The slowdown is biological, not behavioral. Smaller bodies need fewer calories, and counter-regulatory hormones intensify as fat stores shrink.<\/p>\n Several factors emerged from SURMOUNT-1 analysis:<\/p>\n The presence of all six markers typically delivers 20 to 25 percent total loss. The absence of three or more drops average outcomes into the 10 to 14 percent range.<\/p>\n These often matter more clinically than scale numbers.<\/strong> By year 1, the typical Zepbound patient shows:<\/p>\n SURMOUNT-1 and the broader SURPASS program both reported these changes consistently. Many patients reduce or eliminate antihypertensive and statin medications by the end of year 1, though this should be done with provider oversight.<\/p>\n Key Takeaway: Roughly 70 percent of weight loss occurs in the first 6 to 8 months; the rest comes slowly<\/p>\n Mostly maintenance with slow additional losses.<\/strong> The SURMOUNT-1 extension data and the SURMOUNT-4 maintenance trial both suggest that patients continuing tirzepatide through year 2 maintain their losses and often add another 1 to 4 percent.<\/p>\n SURMOUNT-4 (Aronne et al. 2024 JAMA) randomized patients who had completed initial weight loss to either continue tirzepatide or switch to placebo. The placebo group regained about 14 percent. The tirzepatide group lost an additional 5.5 percent.<\/p>\n So continuation works. Discontinuation typically leads to regain that returns most of the benefit within 12 to 18 months.<\/p>\n The framing has shifted in obesity medicine.<\/strong> Tirzepatide is now generally viewed as long-term therapy similar to medications for hypertension or hyperlipidemia, rather than a short-term weight loss tool.<\/p>\n Reasons to continue past year 1:<\/p>\n Reasons to reduce or stop:<\/p>\n TrimRx providers typically build year 1 to year 2 transition plans based on goals and tolerance, with a free assessment quiz used to update treatment plans annually.<\/p>\n Below 10 percent loss at year 1 is uncommon on therapeutic doses but does happen.<\/strong> Things to address:<\/p>\n In trial data, true non-responders (less than 5 percent loss at 1 year despite 15 mg dosing) made up less than 5 percent of patients. Most apparent non-response is actually under-dosing or behavioral.<\/p>\n Maintenance protocols vary, but the core principles are stable:<\/p>\n The shift in mindset is from active weight loss to chronic disease management. The drug is doing maintenance work, not deficit creation, and the lifestyle changes from year 1 carry through.<\/p>\n Bottom line: Cardiometabolic markers (BP, A1c, lipids) often normalize by month 12<\/p>\n For a 250-pound starting weight, 50 pounds is 20 percent, which is right at the SURMOUNT-1 10 mg average. For 200 pounds, it’\\”s 25 percent, which is in the top quartile. For 320 pounds, it’\\”s 16 percent, slightly below average but still meaningful.<\/p>\n Usually slowly. Most patients add another 2 to 5 percent in year 2 if they continue, then plateau. A few patients keep losing into year 3.<\/p>\n Only if you’\\”ve hit goal weight or are very close. Premature dose reduction tends to cause weight creep. Stay at the dose that produced your loss until weight has been stable for 3 to 6 months.<\/p>\n The longest tirzepatide data runs about 3 years (SURMOUNT extensions). Safety has remained strong. The semaglutide cardiovascular safety data from SELECT (Lincoff et al. 2023 NEJM) extends much longer and is reassuring for the drug class.<\/p>\n Generally not advisable. SURMOUNT-4 showed regain after stopping. Weekly dosing is the standard, with no benefit to drug holidays.<\/p>\n Often a sign of dose drift or behavioral slippage during a stressful period. A check-in with your provider, a return to careful protein tracking, and confirmation of injection technique usually addresses it.<\/p>\n Worth doing if available. DEXA shows lean mass and bone density, both of which matter for long-term function. A 1-year DEXA also gives a baseline for ongoing maintenance.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" A full year of Zepbound.<\/p>\n","protected":false},"author":11,"featured_media":93573,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Zepbound Results After 1 Year: Realistic Weight Loss Expectations","_yoast_wpseo_metadesc":"A full year of Zepbound\u00ae. That'\\''s 52 weekly injections, three or four dose adjustments, dozens of small course corrections, and a slowly shifting...","_yoast_wpseo_focuskw":"zepbound results after","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[14],"tags":[42,56,58],"class_list":["post-91091","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-zepbound","tag-results","tag-weight-loss","tag-zepbound"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/91091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=91091"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/91091\/revisions"}],"predecessor-version":[{"id":92097,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/91091\/revisions\/92097"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93573"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=91091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=91091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=91091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
Why Is Year 1 the Most Important Year?<\/h2>\n
What Dose Are Most Patients on at Year 1?<\/h2>\n
How Does Weight Loss Change Through the Year?<\/h2>\n
\n
What Predicts a Strong 1-year Result?<\/h2>\n
\n
What About Cardiometabolic Improvements?<\/h2>\n
\n
What Does Year 2 Look Like?<\/h2>\n
How Do You Decide Whether to Stay on It?<\/h2>\n
\n
\n
What If Your Year 1 Results Are Below Average?<\/h2>\n
\n
How Do You Maintain After the Active Loss Phase?<\/h2>\n
\n
FAQ<\/h2>\n
Is 50 Pounds in 1 Year a Normal Zepbound Result?<\/h3>\n
Will Weight Loss Continue Into Year 2?<\/h3>\n
Should I Drop to a Lower Dose at Year 1?<\/h3>\n
Are There Long-term Safety Concerns?<\/h3>\n
Can I Take a Break From Injections at Year 1?<\/h3>\n
What If I’\\”ve Regained 5 Pounds at Year 1?<\/h3>\n
Should I Get a DEXA Scan at 1 Year?<\/h3>\n